Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 1,313

Document Document Title
WO/1993/002095A1
In the field of organic chemistry, and therapeutical chemistry in particular, 6-substituted 19-nor pregnanes are provided which are selected from the group consisting of 6-substituted 3-keto-DELTA4-19-nor-pregnenes having partial formula...  
WO/1993/000354A1
Described is a method for the preparation of 6-methylene steroids of general formula (I), in which X represents the CD ring system of the androstane-series or pregnane-series steroids, from steroids of general formula (II), in which X is...  
WO/1992/022300A1
The invention relates to chemotherapy and concerns particularly the preparation of pharmaceutical compositions for ocular application, said compositions being characterized in that they contain at least one selected compound of steroidal...  
WO/1992/015604A1
Compounds are provided which are highly selective inhibitors of the cytochrome P-450C17, commonly known as 17,20-lyase enzyme, responsible for androgen biosynthesis. These compounds can be administered to patients to inhibit the producti...  
WO/1992/013873A1
Compounds of general formula (I), in which formula the 1,2-position is satured or is a double bond, R1 is hydrogen or a straight or branched hydrocarbon chain, R2 is a hydrogen or a straight or branched hydrocarbon chain, R3 is acyl, X1 ...  
WO/1992/013872A1
Compounds of general formula (I) in the form of a 22R and 22S epimer, wherein X1 and X2 are the same or different and each represents a hydrogen atom or a fluorine atom, provided that X1 and X2 are not simultaneously a hydrogen atom, pro...  
WO/1992/011277A1
Compounds have general formula (I), in which X stands for an oxygen atom or for the hydroxyimino grouping >N$m(k)OH; R?1¿ stands for a hydrogen atom or for a methyl group; G stands for a hydrogen, halogen atom, a C¿1?-C¿4? alkyl resid...  
WO/1992/011278A1
New compounds having the general formula (I), as well as their pharmacologically acceptable addition salts with acids, are disclosed. In the formula (I), either (Ia) R?11¿ stands for a hydrogen atom in the $g(b) position, whereas R?12¿...  
WO/1992/011279A1
A new type of D-homo-(16-en)-11$g(b)-aryl-4-estrenes having general formula (I), as well as their pharmacologically acceptable addition salts with acids are disclosed. In formula (I), X stands for an oxygen atom, the hydroxyimino groupin...  
WO/1992/008730A1
A novel method is provided for crystallizing organic and particularly steroidal substances. In particular, a crystallization method is provided whereby a predeterminable and homogenous particle size class can be obtained non-mechanically...  
WO1990012577A3  
WO/1992/001454A1
The present invention relates to the use of 20(R)-22-oxavitamin D analogues for treatment or prevention of skin ageing, and to the use of such compounds for preparation of pharmaceutical compositions for treatment and/or prevention of sk...  
WO/1992/000010A1
Invented is a method of treating human prostatic adenocarcinoma by employing a steroid 5-alpha-reductase inhibiting compound or a combination of steroid 5-alpha-reductase inhibiting compounds.  
WO/1991/019731A1
Novel angiostatic $g(D)?4,9(11)�-steroids (I), C�21?-oxygenated steroids (II) and other known steroidal compounds have been found to be useful in treating angiogenesis in mammals who have a need for the same. These steroids are usefu...  
WO/1991/018570A1
The progesterone analog ST1435 has now been found to attain therapeutically effective levels upon topical application to the skin. ST1435 can be administered topically either in liquid or semisolid base such as a cream or gel or in a sol...  
WO/1991/016897A1
Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-ammobutyric acid/benzodiazepine r...  
WO1991014700A3  
WO/1991/014700A2
A process for preparing novel corticosteroid intermediates of formula (XXX) are disclosed. The process entails contacting a 9alpha-hydroxysteroid of formula (XX) with (A) in step (a) an anhydride, an organic acid and an acid reagent havi...  
WO/1991/005557A1
Antigestagens (competitive progesterone antagonists) are suitable for the manufacture of medicaments to treat breast cancers with an increased content of tumour cells in the S phase of the cell cycle, regarded as of high risk.  
WO/1991/004984A1
The present invention relates to a novel process for the manufacture of (22 R,S)-16alpha, 17alpha-butylidenedioxy-11beta, 21-dihydroxypregna-1,4-diene-3,20-dione (I) by reacting 11beta, 16alpha, 17alpha, 21-tetrahydroxypregna-1,4-diene-3...  
WO/1991/004030A1
Disclosed is a method for enhancing the production of T cell lymphokines, which comprises exposing T cell lymphocytes which have a potential to make selected T cell lymphokines to an appropriate concentration of at least one particular s...  
WO/1991/003245A1
Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions ar disclosed. The compositions contain a combination of a glucocorticoid and an angios...  
WO/1991/001991A1
Introduction of a C-12 substituent and especially a beta C-12 substituent into glucocorticoids improves their usefulness as topical anti-inflammatories by increasing their topical activity relative to their systemic activity, thus reduci...  
WO/1990/015068A1
The present invention is a process for conversion of DELTA16-steroids (I), to the corresponding DELTA17(20)-20-silyl ether (III), by reaction with (1) a preformed copper hydride or a metal hydride reducing agent in the presence of a copp...  
WO/1990/012577A2
A method of inhibiting hair growth in mammals which comprises the topical administration of a composition comprising an anti-angiogenic effective amount of an angiostatic compound of formula (I). The formula (I) compound is present in an...  
WO1990009394A3  
WO/1990/012027A1
The invention, which relates to the domain of chemistry and in particular therapeutic chemistry, essentially has as its subject matter b-methyl 19-nor pregna 4,6-dienes 17alpha, and if necessary, 21-alkylates of general formula (I) in wh...  
WO/1990/011290A1
The invention concerns a method for the preparation of 3-desoxy-4-ene steroids of the general formula I in which R¿1?, R¿2? and R¿3? are a hydrogen atom or a methyl group, R¿4? is a lower alkyl group, a phenyl group or a free, esteri...  
WO/1990/009394A2
The process of the present invention is a process for the preparation of an 11-oxygenated steroid of formula (II) which comprises (1) contacting a 9alpha-halo steroid of formula (I) with a metal selected from the group consisting of tin ...  
WO/1990/008128A1
Compounds of formula (I), wherein D represents the dehydrogenated residue of a hydroxyl group-containing drug or the dehydrogenated residue of an NH-acidic group-containing drug; the substituents in the phenyl ring alpha and beta are in ...  
WO/1990/000559A1
Androstane derivatives of general formula (I) wherein R1 denotes a hydrogen atom or a methyl group, X and Y each denote a hydrogen atom or together denote a carbon-carbon bond, R2 denotes a hydrogen atom or an alkyl group with 1 to 6 car...  
WO/1990/000174A1
The invention concerns 13-Alkyl-11beta-phenylgonanes of general formula (I), wherein Z, R1, R2, R3 and R4 have the meaning given, a process for their preparation, pharmaceutical preparations containing these compounds, and their use for ...  
WO/1989/012448A1
An 11beta-aryl-19-norprogesterone steroid of formula (I): wherein (i) R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5, wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl, ...  
WO/1989/010963A1
Genetically engineered host cells containing new expression cassettes are provided which are able to carry out biochemical oxidations of steroids. In particular the oxidation is carried out with cells into which DNA has been introduced w...  
WO/1989/009781A1
New 9alpha-hydroxy-17-methylene steroids are prepared by the introduction of a substituted 17-methylene group in 9alpha-hydroxyandrost-4-ene-3,17-dione. The resulting compounds are useful starting compounds in the synthesis of corticoste...  
WO/1989/006231A1
This invention concerns chemiluminescent moieties useful as labels in assays and immunoassays, and compositions and assay kits incorporating the moieties. The chemiluminescent moieties are of the type wherein attack by peroxide or molecu...  
WO/1989/002272A1
A method of using 3-hydroxylated-5-reduced steroids and certain novel derivatives which act at a newly identified site on the GBR complex, to modulate brain excitability in a manner which will alleviate stress, anxiety, and seizure activ...  
WO/1989/001483A1
The invention involves a two-step chemical transformation of a steroidal 17-cyanohydrin of formula (II) to a 17alpha-hydroxy-21-halo-20-keto steroid of formula (IV) intermediate which can readily be converted to pharmaceutically useful c...  
WO/1989/001327A1
A composition based on hydrated lipidic lamellar phases or liposomes is characterized in that said phases or said liposomes contain, at least in part, pregnenolone or a pregnenolone ester, in particular pregnenolone acetate, sulphate or ...  
WO/1989/001482A1
The present invention involves improved processes for the dehalogenation of 9alpha-halosteroids (I), to produce the corresponding 11beta-hydroxy steroids (II), which are known to be useful as pharmaceutical, where the improvements compri...  
WO/1989/000558A1
Amine salts of alkane-1,n-dicarboxylic acid mono-(2-sulfato-ethyl)amides of the formula (I): HOC(O)-(CH2)n-C(O)-N(R1)-CH2CH2SO3 - + HN(R2)3, wherein R1 is selected from the group consisting of hydrogen, C1-C8 alkyl and phenyl, R2 is C1-C...  
WO/1988/009337A1
This invention concerns a method of substituting a chlorine atom for a predetermined hydrogen atom located within an organic compound which comprises contacting the organic compound containing the predetermined hydrogen atom with an este...  
WO1988002753A3  
WO/1988/003534A1
17beta-Cyano-17alpha-hydroxy steroids (I) are transformed to 17alpha-halo silyl ethers (II) which are intermediates useful in the production of progesterones (V), 17-hydroxyprogesterones (VI), corticoids (VII) and 21-halo corticoids (III...  
WO/1988/002753A2
New 9-alpha-hydroxy steroids are prepared by the introduction of substituents on the D-ring of 9-alpha-hydroxy-androst-4-ene-3,17-dione. The resulting compounds are useful intermediates in the synthesis of corticosteroids.  
WO/1987/007895A1
Androstane-type aminoesters (IV) and cortical aminoesters (VIII), more particularly 17-aminoesters (I), 11,17-diaminoesters (II), 3,17-diaminoesters (III), 21-aminoesters (V), 11-aminoesters (VI), and 3-aminoesters (VII) which are useful...  
WO/1987/007612A1
Process for the production of a DELTA17(20)-steroid of formula (II) which comprises starting with a 16-unsaturated corticoid of formula (I) and contacting the 16-unsaturated corticoid (I) with a methylating agent in the presence of a cop...  
WO/1987/005028A1
Compounds of formula (I), wherein one X is COOR, CH2COOR, CH(COOR)2, CONHR, CH2CONHR, or CN; remaining X's are H, F, CH3, OH, COOR, CH2COOR, CH(COOR)2, CONHR, CH2CONHR, or CN; Y is (i1), (i2), (i3), (i4), or (i5); R is H, alkyl of 1-5 ca...  
WO1987001706A3  
WO/1987/002672A1
Novel tetrahydro steroids which are useful in inhibiting angiogenesis and have the following structure: A compound of formula (I), wherein R15 is = O or -OH; wherein R23 with R10 forms a cyclic phosphate of formula (II) or wherein R23 is...  

Matches 201 - 250 out of 1,313